ESMO - Eur. Oncology· @myESMO · X·· 2 天前评分90
正文 · 机器翻译
#ESMO26：在可切除的肌肉浸润性 #BladderCancer（#MIBC）中，KEYNOTE-866 或 ENERGIZE #ClinicalTrials 试验显示，围手术期使用 pembrolizumab 或 nivolumab 均未显著延长无事件生存期，正如 @y_loriot 所讨论的
🔗 https://ow.ly/TbzF50ZZ0s2
#InsightsbyESMO
1577 浏览 · 14 赞 · 7 转发 · 1 回复
会议摘要
4735O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.org帖内回复
- MeDucation@MeDucationai
@myESMO @y_loriot Worth reading next to NIAGARA, where perioperative durvalumab with gemcitabine-cisplatin did improve EFS and OS, so the question for fellows is what differed in design, population and the adjuvant phase rather than whether the class works here.
来源：ESMO - Eur. Oncology · x.com